Clin2
NCT06106906Possibly a fitRecruiting

CD19 CAR-T for Active Lupus

Systemic Lupus Erythematosus

Treatments studied

Part of Immune system & allergy, Skin clinical trials.

This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
15 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must have been diagnosed with lupus (SLE) for at least 6 months
  • Your lupus must be active (scored 6 or higher on a standard activity scale)
  • You need to have tried lupus treatments for at least 2 months before joining
  • Your weight must be at least 88 pounds (40 kg)
  • Women must not be pregnant and must agree to use birth control during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06106893Recruiting· Phase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus

This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.

Wuhan, Hubei
NCT06349343Recruiting· Phase 1
CAR-T cell therapy for hard-to-treat lupus

This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.

Wuhan
NCT06711146Recruiting· Early Phase 1
CAR T-cell therapy for active lupus

This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.

Hangzhou, Zhejiang
NCT06350110Recruiting· Phase 1/Phase 2
CAR T cells for lupus

This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.

Beijing, Beijing Municipality
NCT07331467Recruiting· Phase 1
Ultra-fast CAR-T cell therapy for lupus

This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.

Nanjing, Jiangsu
NCT07233642Recruiting· Phase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment

This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.

Hangzhou, Zhejiang

Hear when a new Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.